Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EASi-PROTKT study of vicadrostat plus empagliflozin in adults with type 2 diabetes, hypertension, and established cardiovascular disease
NL-OMON59082Phase 3Recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in type 2 diabetes mellitus (T2DM), hypertension (HTN) and cardiac morbidity comparing Vicadrostat + empagliflozin with Vicadrostat-placebo + empagliflozin (2 arms). Primary endpoint: Time to first event of cardiovascular death or heart failure event. Started Dec 2025; status: recruiting.
02
Drugs
vicadrostatempagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)hypertension (HTN)cardiac morbidity
Beyond the preview
Go deeper on NL-OMON59082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59082.